SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

MARKSANS PHARMA

BSE: 524404 30 Sep 2025
Healthcare
₹ 165
Marksans Pharma Ltd. specializes in Pharmaceuticals within the Healthcare sector.

MARKSANS PHARMA - Share Price & Details

Market Cap
₹7,449
High /Low
359.0 / 162.0
Stock P/E
21.3
Book Value
₹54.4
Dividend Yield
0.49
ROCE
20.0
ROE
₹16.8
Face Value
1.0
PEG Ratio
0.78
EVEBITDA
₹12.6
Debt
322
CMP / FCF
92.5
Debt to equity
₹0.13
NP Ann
383
High price all time
359.0
Piotroski score
₹3.0
Graham Number
97.3
No. Eq. Shares
45.3
Net CF
₹92.5
Net profit
352
Price to book value
3.02
Interest Coverage
₹32.1
Low price all time
1.27
Industry PE
33.0
Reserves
₹2,422
Free Cash Flow
₹35.0

Broker Recommendations

No broker recommendations available

We couldn’t find any recent recommendations for this company (matched by symbol or BSE code). Please check back later.


Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
MARKSANS PHARMA LTD.3217.44480.563197.341.067,44921.3
FDC LTD.6778.671221.916422.817.51739427.5
KOVAI MEDICAL CENTER & HOSPITANANANANA6927120.0

Peer Comparison Chart


About MARKSANS PHARMA

Marksans Pharma Ltd., with Security Code 524404, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

Following recent decline, Marksans Pharma Limited's (NSE:MARKSANS) top shareholder CEO Mark Saldanha sees holdings value drop by 8.2%

(27 Sep 2025)
Key Insights Insiders appear to have a vested interest in Marksans Pharma's growth, as seen by their sizeable ownership...
Read more →

Marksans Pharma Hits New 52-Week Low at Rs. 162.45

(26 Sep 2025)
Marksans Pharma has reached a 52-week low, reflecting a significant decline in its stock performance. Over the past year, the company has experienced a...
Read more →

Marksans Pharma’s UK Subsidiary Relonchem Gets MHRA Approval for Moxonidine Tablets

(24 Sep 2025)
Marksans Pharma Ltd on Tuesday said its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorisation from the UK...
Read more →

Marksans Pharma arm wins UK nod for high blood pressure drug Moxonidine

(23 Sep 2025)
Marksans Pharma Ltd on Tuesday announced that its wholly owned UK subsidiary, Relonchem Limited, has received marketing authorisation from...
Read more →

Relonchem receives UK MHRA approval for Moxonidine 200mg/400 mg tablets

(23 Sep 2025)
Marksans Pharma announced that its wholly owned subsidiary Relonchem in UK has received Marketing Authorization for the below-mentioned...
Read more →

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants

(23 Sep 2025)
Relonchem receives marketing authorization for Moxonidine tablets. Marksans Pharma Limited's wholly owned subsidiary Relonchem Limited in UK...
Read more →